Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists
β-Adrenoceptor antagonists boast a 50-year use for symptomatic control in numerous cardiovascular diseases. One might expect highly selective antagonists are available for the human β-adrenoceptor subtype involved in these diseases, yet few truly β1-selective molecules exist. To address this clinica...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Published: |
American Chemical Society
2013
|
| Online Access: | https://eprints.nottingham.ac.uk/30316/ |
| _version_ | 1848793962517626880 |
|---|---|
| author | Mistry, Shailesh N. Baker, Jillian G. Fischer, Peter M. Hill, Stephen J. Gardiner, Sheila M. Kellam, Barrie |
| author_facet | Mistry, Shailesh N. Baker, Jillian G. Fischer, Peter M. Hill, Stephen J. Gardiner, Sheila M. Kellam, Barrie |
| author_sort | Mistry, Shailesh N. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | β-Adrenoceptor antagonists boast a 50-year use for symptomatic control in numerous cardiovascular diseases. One might expect highly selective antagonists are available for the human β-adrenoceptor subtype involved in these diseases, yet few truly β1-selective molecules exist. To address this clinical need, we re-evaluated LK 204-545 (1),1 a selective β1-adrenoceptor antagonist, and discovered it possessed significant partial agonism. Removal of 1’s aromatic nitrile afforded 19, a ligand with similar β1-adrenoceptor selectivity and partial agonism (log KD of −7.75 and −5.15 as an antagonist of functional β1- and β2-mediated responses, respectively, and 34% of the maximal response of isoprenaline (β1)). In vitro β-adrenoceptor selectivity and partial agonism of 19 were mirrored in vivo. We designed analogues of 19 to improve affinity, selectivity, and partial agonism. Although partial agonism could not be fully attenuated, SAR suggests that an extended alkoxyalkoxy side chain, alongside substituents at the meta- or para-positions of the phenylurea, increases ligand affinity and β1- selectivity. |
| first_indexed | 2025-11-14T19:08:38Z |
| format | Article |
| id | nottingham-30316 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:08:38Z |
| publishDate | 2013 |
| publisher | American Chemical Society |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-303162020-05-04T16:36:22Z https://eprints.nottingham.ac.uk/30316/ Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists Mistry, Shailesh N. Baker, Jillian G. Fischer, Peter M. Hill, Stephen J. Gardiner, Sheila M. Kellam, Barrie β-Adrenoceptor antagonists boast a 50-year use for symptomatic control in numerous cardiovascular diseases. One might expect highly selective antagonists are available for the human β-adrenoceptor subtype involved in these diseases, yet few truly β1-selective molecules exist. To address this clinical need, we re-evaluated LK 204-545 (1),1 a selective β1-adrenoceptor antagonist, and discovered it possessed significant partial agonism. Removal of 1’s aromatic nitrile afforded 19, a ligand with similar β1-adrenoceptor selectivity and partial agonism (log KD of −7.75 and −5.15 as an antagonist of functional β1- and β2-mediated responses, respectively, and 34% of the maximal response of isoprenaline (β1)). In vitro β-adrenoceptor selectivity and partial agonism of 19 were mirrored in vivo. We designed analogues of 19 to improve affinity, selectivity, and partial agonism. Although partial agonism could not be fully attenuated, SAR suggests that an extended alkoxyalkoxy side chain, alongside substituents at the meta- or para-positions of the phenylurea, increases ligand affinity and β1- selectivity. American Chemical Society 2013-04-24 Article PeerReviewed Mistry, Shailesh N., Baker, Jillian G., Fischer, Peter M., Hill, Stephen J., Gardiner, Sheila M. and Kellam, Barrie (2013) Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists. Journal of Medicinal Chemistry, 56 (10). pp. 3852-3865. ISSN 0022-2623 http://pubs.acs.org/doi/abs/10.1021/jm400348g doi:10.1021/jm400348g doi:10.1021/jm400348g |
| spellingShingle | Mistry, Shailesh N. Baker, Jillian G. Fischer, Peter M. Hill, Stephen J. Gardiner, Sheila M. Kellam, Barrie Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title | Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title_full | Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title_fullStr | Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title_full_unstemmed | Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title_short | Synthesis and in vitro and in vivo characterization of highly β1-Selective β-Adrenoceptor partial agonists |
| title_sort | synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists |
| url | https://eprints.nottingham.ac.uk/30316/ https://eprints.nottingham.ac.uk/30316/ https://eprints.nottingham.ac.uk/30316/ |